Physician profile
Marc Stegman
NPI 1023019825
$41,075.86
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,775 · 2020: $3,263 · 2021: $6,218 · 2022: $17K · 2023: $11K · 2024: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,000 · Food and Beverage: $2,932 · Travel and Lodging: $2,573 · Education: $81.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,000.00 |
| Food and Beverage | $2,932.48 |
| Travel and Lodging | $2,573.01 |
| Education | $81.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $27,529.27 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $4,242.55 | 2019-2023 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $3,633.96 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $1,153.54 | 2019-2024 | Jynarque |
| Amgen INC. | $623.59 | 2019-2023 | Tavneos, Aranesp, Parsabiv |
| Mallinckrodt Hospital Products INC. | $552.05 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $507.05 | 2022-2024 | |
| Travere Therapeutics, INC. | $455.16 | 2021-2024 | |
| Vifor Pharma, INC. | $366.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $360.20 | 2021-2023 | Benlysta |
| Ardelyx, INC. | $342.15 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Alexion Pharmaceuticals, INC. | $281.31 | 2019-2022 | |
| Horizon Therapeutics Plc | $258.11 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $152.09 | 2022-2023 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $131.64 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $119.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $118.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $88.63 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $42.14 | 2022 | |
| La Jolla Pharmaceutical Company | $42.07 | 2021 | |
| Genzyme Corporation | $39.51 | 2019-2022 | |
| Akebia Therapeutics INC | $23.00 | 2022 | |
| Amicus Therapeutics, INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Stegman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.